Technological paradigms and trajectories as determinants of the R&D corporate change in drug discovery industry
by Mario Coccia
International Journal of Knowledge and Learning (IJKL), Vol. 10, No. 1, 2015

Abstract: The present inductive study shows two main effects of new technological paradigms in medicine driven by convergent genomics, genetics and proteomics (e.g., targeted therapies): 1) division of scientific/technological labour by strategic alliances among firms to reinforce the integrative capabilities in different biomedical research fields in order to support drug discovery process; 2) cumulative and collective learning by network R&D organisations to integrate in-house R&D and external sources of innovation in order to accelerate the discovery of path-breaking drugs for personalised healthcare. Relationships between observed facts are analysed to establish some general implications concerning the impact of technological paradigms on R&D corporate change for supporting the modern discovery process.

Online publication date: Sun, 09-Aug-2015

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Knowledge and Learning (IJKL):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com